6,778 Shares in Boston Scientific Corporation $BSX Bought by Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 6,778 shares of the medical equipment provider’s stock, valued at approximately $728,000.

Several other large investors have also recently added to or reduced their stakes in BSX. Lombard Odier Asset Management Switzerland SA increased its stake in Boston Scientific by 19.5% during the second quarter. Lombard Odier Asset Management Switzerland SA now owns 68,527 shares of the medical equipment provider’s stock valued at $7,360,000 after purchasing an additional 11,159 shares during the last quarter. State Street Corp lifted its position in shares of Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after buying an additional 713,379 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in shares of Boston Scientific by 11.0% in the 2nd quarter. Daiwa Securities Group Inc. now owns 271,940 shares of the medical equipment provider’s stock valued at $29,209,000 after buying an additional 26,891 shares during the period. Gerber Kawasaki Wealth & Investment Management grew its position in shares of Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 99 shares during the last quarter. Finally, SVB Wealth LLC bought a new stake in shares of Boston Scientific during the 2nd quarter valued at about $794,000. 89.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BSX has been the topic of a number of recent research reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Robert W. Baird increased their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. UBS Group boosted their price objective on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Wells Fargo & Company increased their target price on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research report on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and a consensus target price of $123.77.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. This represents a 21.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 143,095 shares of company stock worth $14,228,950 over the last quarter. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Trading Down 4.0%

Shares of BSX stock opened at $93.66 on Tuesday. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The firm has a market capitalization of $138.84 billion, a PE ratio of 50.08, a price-to-earnings-growth ratio of 1.96 and a beta of 0.67. The stock has a fifty day moving average of $99.20 and a two-hundred day moving average of $101.95. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.